Author(s):
Kalpesh Upadhyay, Jaswandi Mehetre, Vimal Kumar, Tushar Mehta, Anirban Roy Chowdhury, Keyur Ahir
Email(s):
Kalpesh.aol@gmail.com , kalpeshu@amneal.com
DOI:
10.52711/2231-5675.2025.00021 
Address:
Kalpesh Upadhyay*, Jaswandi Mehetre, Vimal Kumar, Tushar Mehta, Anirban Roy Chowdhury, Keyur Ahir
School of Pharmacy, ITM SLS Baroda University, Halol highway, Vadodara 391510, Gujarat, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Nitrosamine impurities are a class of substances formed from the reaction of a nitroso compound and secondary or tertiary amines under acidic conditions. The detection of nitrosamine impurities in Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceuticals (FP) has raised significant health concerns due to their potent genotoxic carcinogenic properties. The presence of low concentration levels of nitrosamine impurities has led to drug withdrawals and extensive investigations into their formation. For the estimation of such low level of impurities led to development of highly sensitive and selective analytical methods for the simultaneous determination and quantification of various nitrosamine impurities in active pharmaceutical ingredients (APIs) and Finished Pharmaceuticals (FP). This review evaluates common analytical techniques for nitrosamine impurities detection, including Gas Chromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). It compares their sensitivity, specificity, and practical applications, and discusses sample preparation methods such as Solid-Phase Extraction (SPE), Liquid-Liquid Extraction (LLE) etc. The choice of method depends on sample type, required sensitivity and as per regulatory expectation.
Cite this article:
Kalpesh Upadhyay, Jaswandi Mehetre, Vimal Kumar, Tushar Mehta, Anirban Roy Chowdhury, Keyur Ahir. Various Analytical Techniques used for Nitrosamine impurities in Pharmaceutical Dosage Forms: A Comprehensive Review. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):131-6. doi: 10.52711/2231-5675.2025.00021
Cite(Electronic):
Kalpesh Upadhyay, Jaswandi Mehetre, Vimal Kumar, Tushar Mehta, Anirban Roy Chowdhury, Keyur Ahir. Various Analytical Techniques used for Nitrosamine impurities in Pharmaceutical Dosage Forms: A Comprehensive Review. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):131-6. doi: 10.52711/2231-5675.2025.00021 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-2-10
REFERENCES:
1. Griesenbeck JS, Steck MD, Huber JC, Sharkey JR, Rene AA, Brender JD. Development of estimates of dietary nitrates, nitrites, and nitrosamines for use with the short willet food frequency questionnaire. Nutr J. 2009; 8:16. https://doi.org/ 10.1186/1475-2891-8-16.
2. Park J-E, Seo J-E, Lee J-Y, Kwon H. Distribution of seven N-nitrosamines in food. Toxicol Res. 2015; 31(3): 279–288. https://doi.org/10.5487/tr.2015.31.3.279.
3. Song P, Wu L, Guan W. Dietary nitrates, nitrites, and nitrosamines intake and the risk of gastric cancer: a meta-analysis. Nutrients. 2015;7(12):9872–9895. https:// doi.org/ 10.3390 /nu7125505.
4. Chun-Cheng F, Tsair-Fuh L. N-nitrosamines in drinking water and beer: detection and risk assessment. Chemosphere. 2018; 200:48–56. https://doi.org/10.1016/ j. chemosphere. 2018.02. 025.
5. Edwards SH, Rossiter LM, Taylor KM, et al. Tobacco-specific nitrosamines in the tobacco and mainstream smoke of U.S. Commercial Cigarettes. Chem Res Toxicol. 2017; 30(2):540–551. https://doi.org/10.1021/acs.chemrestox.6b00268.
6. Farsalinos KE, Gillman G, Poulas K, Voudris V. Tobacco-specific nitrosamines in electronic cigarettes: comparison between liquid and aerosol levels. Int J Environ Res Public Health. 2015;12(8):9046–9053. https://doi.org/10.3390/ijerph120809046.
7. Miralles P, Chisvert A, Salvador A. Determination of N-nitrosamines in cosmetic products by vortex-assisted reversed-phase dispersive liquid-liquid microextraction and liquid chromatography with mass spectrometry. J Sep Sci. 2018; 41(15): 3143–3151. https://doi.org /10.1002/jssc.201800388.
8. EMA. Nitrosamine Impurities in Human Medicinal Products. 2020. EMEA/H/A-5(3)/ 1490, EMA/369136/2020Available at; https://www.ema.europa.eu/en/documents/ referral/ nitrosamines-emea-h-a53-1490-assessment-report_en.pdf.
9. FDA. Guidance for Industry. Control of Nitrosamine Impurities in Human Drugs. 2021. Available at; https://www.fda.gov/media/141720/download.
10. EMA. Nitrosamine Impurities: Active Substance-Derived Nitrosamines. 2022. Available at; https://www.ema.europa.eu/en/human-regulatory/post-authorisation/ referral-procedures/ nitrosamine-impurities#active-substance-derived-nitrosamines-section.
11. Schmidtsdorff S, Neumann J, Schmidt AH, Parr MK. Risk assessment for nitrosated pharmaceuticals: a future perspective in drug development. Arch Pharm. 2022; 355(4). https://doi.org/10.1002/ardp.202100435.
12. T. Tsutsumi, H. Akiyama, Y. Demizu, N. Uchiyama, S. Masada, G. Tsuji, H. Okuda, Analysis of an impurity, N-nitrosodimethylamine, in valsartan drug substances and associated products using GC-MS, Biol Pharm Bull. 2019; 42: 547–551. https://doi. org/10.1248/bpb.b19-00006
13. H.H. Lim, Y.S. Oh, H.S. Shin, Determination of N-Nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of Sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography– tandem mass spectrometry, J Pharm Biomed Anal. 2020; 189: 113460. https://doi. org/10.1016/j.jpba.2020.113460
14. W. Wichitnithad, O. Sudtanon, P. Srisunak, K. Cheewatanakornkool, S. Nantaphol, P. Rojsitthisak, Development of a sensitive headspace gas chromatography–mass spectrometry method for the simultaneous determination of nitrosamines in losartan active pharmaceutical ingredients, ACS Omega 6 (2021) 11048–11058. https: //doi.org/10.1021/acsomega.1c00982.
15. US Food and Drug Administration, Combined direct injection Nnitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), N-nitrosoethylisopropylamine (NEIPA), N- nitrosodiisopropylamine (NDIPA), and N-nitrosodibutylamine (NDBA) impurity assay by GC-MS/MS. 2019
16. F. Sorgel, M. Kinzig, M. Abdel-Tawab, C. Bidmon, A. Schreiber, S. Ermel, U. Holzgrabe, the contamination of valsartan and other Sartans, part 1: new findings, J Pharm Biomed Anal. 2019; 172: 395–405. https://doi.org/10.1016/j.jpba.2019.05.022.
17. US Food and Drug Administration, Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of NDMA in metformin drug substance and drug product. 2020.
18. US Food and Drug Administration, Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) method for the determination of NDMA in ranitidine drug substance and solid dosage drug product. 2019.
19. B. Vijaya-Kumar, N. Saritha, D. Subba-Rao, J. Mohit, K. Prashanth, S. Sanjeev, K. Pramod, A critical N -nitrosamine impurity of anticoagulant drug, rivaroxaban: synthesis, characterization, development of LC–MS/MS method for nanogram level quantification, Chromatographia. 2022; 85: 73–82. https://doi.org/10.1007/ s10337- 021- 04115- x.
20. S.H. Chang, C.C. Chang, L.J. Wang, W.C. Chen, S.Y. Fan, C.Z. Zang, D.Y. Wang, A multi-analyte LC-MS/MS method for screening and quantification of nitrosamines in sartans, J Food Drug Anal. 2020; 28: 292–301. https://doi.org/10.38212/ 2224-6614.1063.
21. N.K. Nagdella, H. Shaik, S.B. Subramanyam, D. Godugu. M.K.R. Mudiam, Development, validation, and estimation of measurement uncertainty for the quantitative determination of nitrosamines in Sartan drugs using liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry, J Chromatogr Open. 2022; 2: 10053. https://doi.org/ 10.1016/j.jcoa.2022.100053.
22. R. Gonzalez, G. Torrado, J.M. Arribas, M.A. Pena, Development of an analytical method for the determination and quantification of n-nitrosodimethylamine in olmesartan by HPLC-MS/MS, Michrochem J. 2022; 179: 107402, https://doi.org/10.1016/j.microc.2022.107402.
23. A. H. Shaik, R.R. Kotanka, K. Ruthala, S. R. Gandholi, K. Nalla, S. R. Kanade, Development of Single Validation Method for Detection and Quantification of Six Nitrosamine Impurities in Valsartan by Using Ultra-high Performance Liquid Chromatography with Tandem Quadrupole Mass Spectrometry, Int J Phar Sci Rev Res, 2023; 79(2): 143-150. http://dx.doi.org/10.47583/ ijpsrr. 2023.v79i02.023.
24. M. Khorolskiy, G. Ramenskaya, A. Vlasov, O. Perederyaev, N. Maslennikova, Development and Validation of four Nitrosamine Impurities Determination Method in Medicines of Valsartan, Losartan, and Irbesartan with HPLC-MS/MS (APCI), Iran J Pharm Res. 2021; 20(3): 541-552. 10.22037/ijpr.2021.115102.15195.
25. K. S. Chidella, V. B. Dasari, J. Anireddy, Ultra-Sensitive LC-MS/MS Method for the Trace Level Quantification of Six Potential Genotoxic Nitrosamine Impurities in Telmisartan, Am J Analyt Chem. 2021; 12: 227-240. https://www.scirp.org/journal/ajac.
26. J. Liu, B. Xie, B. Mai, Q. Cai, R. He, D. Guo Z. Zhang, J. Fan, W. Zhang, Development of a sensitive and stable GC-MS/MS method for simultaneous determination of four N-nitrosamine genotoxic impurities in sartan substances, J Anal Sci Technol. 2021; 12(3): https://doi.org/10.1186/s40543-020-00254-2.
27. W. Wichitnithad, O. Sudtanon, P. Srisunak, K. Cheewatanakornkool, S. Nantaphol, P. Rojsitthisak, Development of a Sensitive Headspace Gas Chromatography−Mass Spectrometry Method for the Simultaneous Determination of Nitrosamines in Losartan Active Pharmaceutical Ingredients, ACS Omega. 2021; 6: 11048-11058, https://doi.org/10.1021/acsomega.1c00982